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A B S T R A C T
Cancer vaccines are solely meant to amplify the pool of type 1 cytokine oriented CD4+ and CD8+ T cells that
recognize tumor antigen and ultimately foster control and destruction of a growing tumor. They are not designed
to deal with all aspects of immune ignorance, exclusion, suppression and escape that are generally in place in
patients with cancer and may prevent the T cells to enter the tumor or to exert their eﬀector function. This simple
fact prompted for a reappraisal of the many recent trials in which therapeutic cancer vaccines have been ex-
amined as monotherapy. In this review, I focus on trials examining therapeutic cancer vaccines at diﬀerent
stages of existing disease. The analysis of vaccine-induced immune responses and clinical activity of therapeutic
cancer vaccines revealed four levels of evidence for vaccine eﬃcacy. The lowest levels, reﬂect the many trials in
which the strength of the tumor-reactive T cell response of vaccinated patients is associated with better clinical
outcome or change in tumor marker. The highest levels indicate occasional regressions of tumors and metastases
after vaccination or reﬂect a stronger clinical impact of vaccine in a randomized trial. A whole series of trials in
which vaccine-induced tumor immunity correlates with the clinical impact of cancer vaccines in premalignant
diseases, settings of low tumor burden or tumor regressions in patients with cancer, form an attest to the fact that
cancer vaccines work. While the current number of true clinical responders in each cancer trial is too low for ﬁrm
conclusions on immune correlates of clinical reactivity in cancer, extrapolation of the results from vaccinated
patients with pre-cancers suggest a requirement of broad type 1 T cell reactivity.
1. Introduction
The immune system has an important role in the control of tumor
outgrowth. There is the consensus that a strong Th1 cytotoxic micro-
environment is associated with a more favorable prognosis and therapy
responsiveness in many tumor type [1,2]. Harnessing the immune
system to detect and destroy tumors has been a long-term goal in
mankind since the 1891 report of Coley [3]. A number of eﬀective
strategies, including adoptive cell transfer [4,5] and immune check-
point blockade [6,7], have been developed such that immunotherapy of
cancer has become one of the pillars of modern cancer therapy in the
clinic. The response rate to checkpoint therapy varies tremendously per
cancer. Growing evidence indicates that patients lacking pre-existing
tumor immunity are less likely to respond [8,9], suggesting that their
immune system needs to be pre-sensitized to tumor antigens. Cancer
vaccines are excellently suited for this job since they can amplify the
pool of tumor-reactive T cells from the naive repertoire, reactivate
existing tumor-speciﬁc T cells and are able increase the breadth and
diversity of the tumor-reactive T cell response.
The key component of a vaccine is the antigen used to stimulate the
immune system. Initial cancer vaccines were based on cancer cell ly-
sates but the molecular identiﬁcation and characterization of a the ﬁrst
gene reported to encode a deﬁned tumor antigen that was recognized
by tumor-killing CD8+ T cells, boosted the development of potential
cancer vaccines [10]. Since then many suitable target antigens have
been identiﬁed. Tumor antigens can be classiﬁed as tumor associated or
tumor speciﬁc [11]. Many of the cancer vaccines developed aimed to
increase T cell reactivity to self-proteins that are overexpressed, in-
volved in tissue diﬀerentiation or which are expressed by tumor cells
and immune privileged tissue such as the cancer-testis antigens. To-
gether, they form the broad category of tumor associated antigens
(TAA). The preference to use TAA in cancer vaccines was their broader
applicability (e.g. multiple patients with same cancer, cancers of dif-
ferent types sharing antigen expression). There is accumulating
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evidence for the presence of spontaneously activated T cells recognizing
self-proteins that are preferentially expressed by regulatory immune
cells. Vaccines designed to stimulate T cell responses to these antigens
indirectly target tumors by unleashing spontaneous tumor immunity.
However, it turns out that given the self-nature of TAA, responding T
cells are likely to suﬀer from some degree of central tolerance and are
not truly tumor speciﬁc.
The group of tumor speciﬁc antigens (TSA) is formed by the proteins
of oncogenic viruses that are expressed by transformed cells and by
neoantigens generated as products of somatic mutations and frame
shifts. Some of the evidence for the existence and important role of
tumor speciﬁc antigens in tumor control dates back to the early days in
tumor immunology, showing that experimental tumors arising in the
skin after exposure to chemical carcinogens or ultraviolet (UV)light
bear unique tumor-rejection antigens [12,13], whereas virus-induced
tumors displayed viral proteins that functioned as such [14,15]. There
is also data suggesting that a group of TAP-independent self-peptides,
which are only expressed by cells deﬁcient for the peptide transporter
TAP, can act as tumor speciﬁc antigens [16,17]. The development and
impact of preventive cancer vaccines has recently been excellently re-
viewed by Finn [18] and Spira et al. [19]. In this review, the focus is on
therapeutic cancer vaccines, applied at diﬀerent stages of existing dis-
ease. The mechanisms and components required to build eﬀective
therapeutic cancer vaccines and how to deliver them to patients, has
been reviewed excellently by Hu et al. [20].
In the past, the results of cancer vaccines led to a too pessimistic
view on their potential within the immunotherapy space [21,22]. This
view was fueled by large phase III studies with negative outcomes and
based on the misconception that immunotherapy was just a matter of
replenishing the host with tumor-reactive T cells, whereas we now
know that cancer immunity is inﬂuenced by a complex set of host,
tumor and environmental factors [23]. Hence, while vaccines are only
meant to amplify the pool of type 1 cytokine oriented tumor-reactive
CD4+ and CD8+ T cells they were, in fact, expected to deal with all
aspects of immune ignorance, exclusion, suppression and escape.
Therefore, published trials should be appraised in the context of our
current knowledge that the full clinical potential of therapeutic cancer
vaccines can only be determined when appropriate co-treatments are
provided that overcomes systemic and local immune suppression as
well as immune exclusion [24]. In this review, a number of negative
phase III trials are discussed in the context of today’s knowledge of the
tumor microenvironment. Then, a whole series of recent cancer vaccine
trials is reevaluated with respect to their capacity to induce tumor
immunity and the correlation of this immune response to clinical out-
come. Keeping in mind that previously much optimism was based on
surrogate endpoints rather than actual tumor regressions [21], four
levels of evidence for vaccine eﬃcacy on clinical outcome (Fig. 1) were
distinguished.
It turns out that increases in functional tumor-reactive type 1 T cell
responses and regression of lesions or metastases can be observed after
vaccination in quite a number of trials. New studies will require in-
vestigators to address the reasons for successful regressions as this will
lead the way for application of cancer vaccines under the best condi-
tions.
2. Therapeutic vaccination and clinical outcome
2.1. Phase 3 trials with tumor-associated antigens failed for a reason
A series of phase 3 cancer vaccination trials have been reported in
the last couple of years. None of them had a positive outcome.
Considering the task cancer vaccines have, one should revisit these
trials with the knowledge of today, rather than throwing the im-
munotherapeutic potential of cancer vaccines in the waste basket.
One large study evaluated 3 diﬀerent HLA-A*0201 restricted mel-
anoma peptides previously found to elicit a T cell response in 35% of
the stage IV melanoma patients and of which the immune responders
did show higher overall survival (OS) than the non-immune responders
[25]. This resulted in a new randomized, placebo-controlled phase III
study where 815 patients, 436 of which were HLA-A*0201, with
completely resected stage IV melanoma or high-risk stage III were
vaccinated with the peptide vaccine, GM-CSF or both, but no improved
recurrence free survival (RFS) or OS was found [26]. Inspection of
patient demographics teaches us that about 90% of the patients dis-
played absent or sparse inﬁltrate in their primary tumor. Such non-
inﬂamed tumors have a low capacity to attract T cells, and therefore are
not likely to respond to vaccination or other individual im-
munotherapies [23]. This in combination with the apparent low im-
munogenicity of the vaccine would allow only a very small percentage
of patients to respond (10% of 35% makes 3,5% of patients) [25,26]. In
view of our understanding with respect to the role of neoantigen-spe-
ciﬁc T cells in melanoma, targeting of TAA in melanoma is not expected
to drive major clinical successes.
GV1001, targeting telomerase, was tested in randomized phase 3
trial of patients with pancreatic ductal adenocarcinoma to receive ei-
ther gemcitabine/capecitabine chemotherapy or chemotherapy with
sequential GV1001 or chemotherapy with concurrent GV1001 [27].
The immune response was tested in small part of the vaccinated group,
and only measurable by proliferation after> 10 days of in vitro sti-
mulation (IVS). A diﬀerence in response over background of> 1.8 was
deﬁned as positive. Still only 30% of the patients in the sequential
group and 15% of the patients in the concurrent group showed a T cell
proliferative response. In addition, only 12% and 20%, respectively,
showed a positive delayed type hypersensitivity (DTH) response to the
vaccine. There were no diﬀerences in survival [27]. Thus, the vaccine
was able to induce a T cell response in a minority of patients. This
tremendously lowers the number of patients that could show clinical
reactivity. Furthermore, the choice to combine with chemotherapy was
based on pre-clinical mouse models showing a positive eﬀect of gem-
citabine on immune suppressive cells [28,29] and with cancer vaccines
[30]. However, recently it was shown that gemcitabine has an eﬀect on
a phenotypically deﬁned population of myeloid derived suppressor cells
(MDSC) in patients [31] but also that this particular population was not
suppressive. Other MDSC phenotypes that were suppressive were not
decreased by gemcitabine treatment [32]. Neither the impact of the
immunosuppressive cells nor the inﬂuence of the tumor immune con-
texture was assessed within this trial.
IMA901, a vaccine consisting of 9 HLA-class I- and 1 HLA class II-
restricted tumor-associated peptides, was tested in a phase III trial in
patients with metastatic clear cell renal cell carcinoma [33]. Patients
were either treated with sunitinib only or in combination with the
vaccine. There were no diﬀerences in survival. In addition, the pre-
viously reported correlation between survival and the number of epi-
topes recognized [34,35] was not conﬁrmed. An important ﬁnding
within this study was the observation that the CD8+ T cell responses to
the vaccine were 3-fold lower than previously observed in the phase
1–2 trials with this vaccine and type of patients. However, in these
earlier trials sunitinib was not used. The reason to use sunitinib was
based on mouse models showing that levels of regulatory T cells (Tregs)
were reduced, it also has an established clinical eﬀect in renal cell
carcinoma. Studies in patients receiving sunitinib conﬁrmed the re-
duction in Tregs, albeit small. Also, sunitinib treatment has been re-
ported to reduce CD33+, HLA−DR− MDSC and CD15+, CD14−
MDSC [36,37]. However, sunitinib may also aﬀect other myeloid po-
pulations. The authors found a strong reduction in the number of
monocytes after ﬁrst round of sunitinib. This eﬀect on monocytes was
known and is the result of reduced hematopoiesis [38] but sunitinib
also displays other negative eﬀects such as the induction of IL-10 pro-
duction by M1 macrophages [38]. Potentially, the strong eﬀect on
monocytes is also mediated on DC. This is currently unknown but
would be expected and in combination with the modulatory eﬀects on
M1 macrophages it could explain why the T cell response is lower in
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this trial. An important factor that in hind sight could explain failure or
the trial is the existence of at least four molecular subtypes of clear cell
renal cell carcinoma. The subtype associated with a strong in-
ﬂammatory, Th1-oriented but suppressive immune environment is the
least sensitive to sunitinib [39]. This means eﬀectively, that only one
subgroup of patients has an inﬂamed tumor allowing access of vaccine-
induced T cells but it is not clear if these cells could resist the immune
suppressive environment. Furthermore, patients with tumors of one of
the other molecular subtypes are less likely to beneﬁt from the vaccine
but respond better to sunitinib, obscuring vaccine eﬀects on survival.
Three phase 3 trials were performed in non-small cell lung cancer
(NSCLC). The ﬁrst was a placebo-controlled randomized study with
tecemotide, a 25 amino acid long MUC-1 lipopeptide derived from the
tandem repeat region of MUC-1. The vaccine was given as maintenance
therapy to stage III unresectable NSCLC patients with objective re-
sponses or stable disease (SD) after chemotherapy [40]. Three days
before ﬁrst vaccination a low-dose cyclophosphamide was provided,
based on a trial in breast cancer patients showing stronger immunity. In
a preceding phase IIB trial with stage 3b and IV NSCLC patients it was
shown that this regimen had a positive eﬀect on survival in the sub-
group of IIIB patients, hence the phase 3 trial was started. Interestingly,
when the immune response is examined in that trial it turns out that
only 16 of 78 patients tested displayed a MUC-1 speciﬁc T cell pro-
liferative response, two of which had stage 3b disease [41]. No vaccine
associated survival eﬀects were seen in the phase 3 trial, which should
not have come to a surprise in view of the low immunological response
rate in stage 3b patients. The second study in stage 3/4 NSCLC patients
was performed with an allogeneic tumor vaccine, comprising four
TGFβ2 antisense gene modiﬁed (to prevent immune suppression and to
increase immunogenicity) irradiated NSCLC cell lines, as maintenance
therapy. No beneﬁt was found [42]. In an earlier phase 2b, IFNγ Elispot
reactivity to the allogeneic cell lines was found in 17 of 36 patients, the
majority of which were patients with a tumor control of stable disease
or better. However, also allogeneic HLA-speciﬁc antibodies were found
in most of the SD patients, indicating that the T cell reactivity found is
likely targeted to the HLA molecules present on these allogeneic tumor
cells that are foreign to the patient rather than recognizing tumor an-
tigens [43]. The third trial randomized placebo controlled phase 3 trial
comprised a recombinant MAGE-A3 protein vaccine with AS15 im-
munostimulant. It was tested with or without chemotherapy in patients
with stage IB, 2 and 3a MAGE-A3-positive NSCLC [44]. No vaccine
eﬀect was seen on disease free survival (DFS), neither in patients with
nor without concomitant chemotherapy. The validation of a gene-sig-
nature that predicted patients most likely to beneﬁt from vaccination
could not be performed. This gene panel comprising immune related,
Th1/IFNγ genes and chemokines for T cell homing, STAT1 and IRF1
regulated genes, was discovered to predict better DFS in a phase 2
placebo controlled study in NSCLC [45]. Recombinant protein, how-
ever, is not the most immunogenic vaccine concept, their processing by
DC is not optimal [46] and this can also be deduced from the im-
munological responses that were reported earlier for this vaccine. First
of all, spontaneous responses to MAGE3 are very rare and vaccine in-
duced responses were measured only after an IVS of at least 10 days
before the immune response was measured. In the previous trial only in
1 of 9 vaccinated patients with recombinant MAGE-3 protein and in 4 of
8 patients vaccinated with protein and AS02B adjuvant responded with
a type 1 CD4+ T cell response. Furthermore, only 1 out of 9 HLA-A2
and 1 out of 5 HLA-A1 positive patients showed a CTL response after
vaccination, respectively [47]. Thus, two trials are likely to have suf-
fered from the low immunogenicity of the vaccine used, whereas in one
it can be questioned if there were any tumor-speciﬁc responses. In the
ﬁrst trial the choice to go for a certain type of subgroup was based on a
post-hoc analysis. Furthermore, also in NSCLC the immune contexture
plays an important role with respect to the response to immunotherapy.
For instance, NSCLC is known for its notoriously downregulation of
HLA class I and this is associated with loss of the clinical eﬀects of
strong CD8 T cell inﬁltration. The same holds true for the expression of
HLA-E which has a negative impact on inﬁltrating CD8 T cells and is
overexpressed in 70% of the cases [48]. The importance of HLA class I
expression for therapeutic vaccine outcome was also demonstrated in a
metastatic melanoma patient who received an autologous melanoma
vaccine. Three metastatic lesions strongly expressing HLA class I re-
gressed whereas 3 other lesions had low to no HLA class I expression
and progressed [49]. Also, the presence of a type 1 inﬂamed immune
signature is important for responsiveness [50].
Overall it means that a full appreciation of cancer vaccines can only
be obtained when cancer vaccines are trialed in settings that optimally
support their purpose, that is to reinvigorate the T cell response against
tumor antigens, and not asked to overcome the other immunological
problems posed by tumors. It is most likely that vaccination of patients
with cancer requires co-treatment with checkpoint antibodies since
activated T cells will express co-inhibitory molecules [51]. In addition,
upon IFNγ-exposure the tumor will adapt to resist the attack and start to
express the ligands for these co-inhibitory molecules [9]. This needs to
Fig. 1. The levels of evidence for vaccine eﬃcacy. Cancer vaccine trials report vaccine-induced immune responses in the context of diﬀerent clinical observations.
The strength of this evidence for a true impact of the immune response on tumor growth can be considered low to high.
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be counteracted if one wants the vaccine-induced T cells to exert their
function and control tumor growth [52,53].
2.2. All four levels of evidence for vaccine eﬃcacy are observed in phase 1/
2 TAA-vaccine trials
Bearing in mind the several reasons possibly explaining why cancer
vaccines did not show a beneﬁcial eﬀect as single immunotherapeutic
agent, the biological signs for success obtained in phase 2 trials should
be carefully examined and placed into context of the several immune
suppressive and escape mechanisms playing a role in patients with
cancer, as they may obscure true vaccine activity.
2.2.1. HLA class I and II targeting tumor associated antigen vaccines
In ﬁve trials, diﬀerent groups of patients were treated with vaccines
targeting telomerase. Telomeres are shortened at each mitosis, limiting
cell divisions, and tumors reset this clock by expressing telomerase that
synthesizes new telomere units. The reverse transcriptase subunit of
telomerase, hTERT, is often overexpressed and may function as a good
tumor-associated antigen. In a phase 1/2 trial, 26 advanced mostly
stage IV NSCLC patients, not receiving chemo or radiotherapy, were
vaccinated with two telomerase peptides, GV1001 and GV1540.
GV1001 is a 16aa telomerase peptide with promiscuous presentation in
several diﬀerent HLA class II molecules. In 13 of the 24 evaluable pa-
tients a GV1001 response developed. The immune responders displayed
increased survival when compared to the non-responders (Level 1). The
detection of a GV1001 immune response was even after correction of
potential confounders an independent prognostic factor for survival.
Interestingly, 2 patients (stage 3a and stage 3b) were free of disease
after 108 and 93 months and still have detectable T cell responses in
blood [54,55]. In a phase 2 trial 23 inoperable stage III NSCLC patients
received radiotherapy and weekly docetaxel followed by the GV1001
vaccine. In 13 of the 19 tested patients a long-term T cell response,
measured by proliferation after one round of IVS, was found. Again, the
immune responders displayed longer progression free survival (PFS)
than non-responders [55]. A third trial in 46 patients with advanced
NSCLC, having residual or progressive disease following front line
therapy, received two injections with a binding-optimized HLA-
A*0201-restricted TERT peptide and 4 injections with the native pep-
tide. The detection of an immune response to the optimized and/or
native peptide, as measured by ex-vivo IFNγ Elispot was associated with
longer PFS and a signiﬁcantly better OS. Moreover, among the immune
responders there were three patients that had SD when they entered the
trial but of whom the tumors started to shrink after vaccination, leading
to a partial response (PR). In addition, 2 patients developed a SD while
being progressive before vaccination [56]. Thus, in some patients with
at low disease burden, cancer vaccination resulted in objective clinical
responses (Level 3). A case report on a patient with multiple metastatic
lesions of ductal adenocarcinoma of the pancreas and treated 15 times
with monocyte derived DC vaccine electroporated with hTERT mRNA
[57], mentioned that this treatment resulted in a PR and long-term
survival. A broad proliferative response to 9 of 15 tested hTERT pep-
tides was measured. The response comprised IFNγ, TNFα and IL-2
producing CD4+ T cells while no reaction of CD8+ T cells was found.
These responses developed slowly, several months after start of vacci-
nation. In the ﬁfth trial, three long hTERT-derived peptides (UV1),
which were most frequently recognized by CD4+ T cells of long term
cancer survivors, based on epitope spreading following vaccination
with GV1001 [58], were used together with GM-CSF as vaccine in pa-
tients with prostate cancer receiving androgen deprivation treatment
(ADT) as well as radiotherapy between month 4 and 6 of vaccination.
De novo immune responses were detected in 18 of 21 tested patients, as
measured after one round of IVS. The levels of prostate speciﬁc antigen
(PSA) declined in 14 patients (Level 2) and 10 ha d no evidence of
disease at the end of the trial. Progressive disease (PD) was deﬁned as
increase in serum PSA and/or appearance of new lesion. None of the
patients with PD responded to the vaccine whereas the majority of
patients with an SD displayed a response to 2–3 of the peptides. It was
not clear whether the clinical response was due to the vaccine or due to
ADT and radiotherapy [59]. Overall, vaccination against hTERT was
associated with levels 1–3 of vaccine eﬃcacy.
Shared tumor-associated antigens in melanoma were the ﬁrst to be
identiﬁed [10]. Vaccination of stage 4 metastatic melanoma patients
with 3 HLA-A*0201 binding TAA-derived peptides combined either
with GM-CSF or with IFNα2b or with the combination of both adjuvants
revealed that these adjuvants did not improve the immunogenicity of
the peptides. Of the 115 patients analyzed, only 35% made an immune
response to at least one peptide, measured by ex-vivo IFNγ Elispot,
indicating that this vaccine was not highly immunogenic in these pa-
tients. Of the 73 patients with clinical and immune data, 25 patients
displayed a response at any of the two diﬀerent time points studied and
at least to one peptide. Immune responders had a signiﬁcantly longer
OS [25]. In another phase 2 trial, 61 patients with treatment refractory
stage IV metastatic melanoma were vaccinated with 3 HLA class I
binding peptides derived from the amino acid sequence of the tumor
antigen survivin. Fifty-ﬁve patients were evaluable for clinical response
and survival and 41 for immune reactivity [60]. Using ex-vivo IFNγ
Elispot, a survivin-speciﬁc T cell response was detected at least once
during the ﬁrst 16 weeks of vaccination. The detection of a vaccine-
induced type 1 T cell response was detected in 13 of 41 patients and
more frequently observed in patients with less advanced disease and
normal lactate dehydrogenase (LDH) levels, suggesting that less ad-
vanced disease is associated with less systemic immune suppression.
Importantly, in 80% of the patients displaying CR, PR, or SD and only in
20% of the patients with PD a vaccine-induced immune response was
detected, indicating an anti-tumor eﬀect of these T cells. In general,
vaccine-responders displayed a longer overall survival. In a phase 1/2
trial, 53 patients with advanced melanoma (stage III/IV) received a
vaccine consisting of autologous DC loaded with a cocktail of mela-
noma antigen-derived HLA-A*0101 or HLA-A*0201 restricted native
peptides from MAGE-1, MAGE-3, tyrosinase, MAGE-10, and analogues
from MART1, gp100 and NY-ESO1 and 6 HLA class II peptides from
MAGE-3, tyrosinase, gp100 and NY-ESO1. Later a 10-year pre-planned
follow up was performed in [61]. Using diﬀerent immune assays, each
of the patients displayed type 1 T cell responses to almost all possible
HLA class II peptides, sometimes to the HLA-A*0101 restricted peptides
and almost to all of the HLA-A*0201 restricted peptides. Although in
this trial no objective clinical responses were observed according to
WHO criteria, some of the patients displayed slow regressions and
eventually complete disappearance of individual metastases. Further-
more, after 13 years of follow-up, 19% of the patients with measurable
disease are still alive, none of them except for one who received addi-
tional targeted therapy or immunotherapy. There were no correlations
between the magnitude of the responses or the number of epitopes
recognized, as measured after IVS, and clinical outcome, mostly be-
cause all patients responded to almost all epitopes in the vaccine.
However, the intensity of the vaccine-injection site reaction, which may
be a sign of a stronger immune response, was associated with longer OS
(Level 1) [61]. This is reminiscent of other observations showing that
ﬂu-like symptoms and/or vaccine site reactions after vaccination were
correlated with a stronger ex-vivo measured type 1 T cell response
[62,63]. In addition, the emergence of eosinophilia after vaccination,
possibly due to IL-2 and/or GM-CSF produced by the vaccine-activated
T cells, was also signiﬁcantly associated with long term survival in
tumor bearing patients [61]. Thus, these melanoma vaccine trials
provided evidence for vaccine eﬃcacy at levels 1 and 3.
Twelve children with recurrent high-grade glioma were vaccinated
with a cocktail of 3 HLA class I-restricted peptides, derived from the
glioma-associated antigens survivin, IL-13R and EphA2, as well as a pan
HLA-DR binding epitope from tetanus toxoid, all mixed in Montanide
ISA 51 and then injected close to the powerful immune stimulator poly
ICLC. Immune responses were found in 9 of the ten tested children as
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measured by IFNγ Elispot after IVS. All children responded at least to
EphA2 and 3 children also responded to the tetanus-derived helper
epitope. The immune response waned in a few patients but in the other
patients it was maintained for a long time. In one of the patients a level
3 evidence for vaccine eﬃcacy was found. This patient had an ana-
plastic astrocytoma abundantly expressing EphA2, while the other
glioma associated antigens were sporadically expressed. The patient
developed a strong and persisting response to EphA2 and the helper
peptide and this was associated with a very long-lasting PR [64].
Level 4 evidence for vaccine eﬃcacy, that is a better clinical re-
sponse in vaccinated patients versus an appropriate control group of
non-vaccinated patients, was found in vaccinated patients with ovarian
cancer. A vaccine consisting of autologous tumor cells, engineered to
express GM-CSF/bi-shRNA furin DNA to block furin-mediated conver-
sion of TGFβ pro-proteins into active immunosuppressive TGFβ1 and
TGFβ2, was made. In a phase 2 trial, this vaccine was injected into
women with stage III/IV ovarian cancer following CR on de-bulking
surgery and chemotherapy. After the ﬁrst randomization of 20 patients
receiving the vaccine and 11 patients for control, preliminary data
suggested clinical beneﬁt and another 11 patients received only the
vaccine. All 31 vaccinated patients developed a type 1 T cell response as
measured by IFNγ Elispot against pre-processed autologous tumor cells.
Vaccinated patients had a signiﬁcantly longer time to recurrence than
11 non-vaccinated patients [65].
2.2.2. Vaccination with deﬁned HLA class I-restricted antigens
HLA-A24 is the most common HLA class I allele in the Japanese
population. Therefore, a whole series of trials have been performed
with HLA-A24-restricted TAA-peptide vaccines. In a phase 1/2 trial, an
HLA-A*02401 restricted peptide from KIF20A, which is signiﬁcantly
trans-activated in pancreatic cancer, was injected in 29 patients with
metastatic pancreatic cancer who failed gemcitabine therapy. In 16 out
of 23 tested patients the CD8+ T cell response to KIF20A increased and
this was associated with injection site reactions. Level 3 vaccine eﬃcacy
was evident from the one CR and the objective shrinkage of some
metastases in another 8 cases. The patient with a CR showed a strong
and sustained (> 2 years) response to KIF20A as measured by HLA class
I-multimers and IFNγ Elispot. Notably, in 3 cases the objective lesion
shrinkage was not associated with a detectable T cell response, mea-
sured following two weeks of IVS [66], and it is not clear if this is a
technical failure. In a follow-up phase 2 trial 68 chemotherapy naïve
patients with advanced pancreatic cancer patients received 3 HLA-
A*02401 restricted peptides from KIF20A, VEGFR1 and VEGFR2 in
combination with gemcitabine irrespective of HLA type. In the end 38
patients were HLA-A*02401 positive. The PFS and OS did not diﬀer
between HLA-A*2401 positive and negative patients. Among the HLA-
A*02401-positive subjects those who made an IFNγ-associated T cell
response, measured after IVS, to KIF20A and/or VEGFR1 displayed a
better OS. A similar observation was made for those patients with a
strong injection site reaction [67]. A phase 2 study with OCV-C01
vaccine consisting of peptides from KIF20A, VEGFR1 and VEGFR2 with
gemcitabine as adjuvant treatment for 30 surgically treated pancreatic
cancer patients that were HLA-A*2402. 15 HLA-A*2402 negative pa-
tients received gemcitabine only. Possibly level 4 evidence for vaccine
eﬃcacy was found since the vaccinated patients had a better – but not
signiﬁcant - DFS than non-vaccinated patients. More than half of the
patients displayed a CTL response to KIF20A, and this was associated
with longer survival. Importantly, KIF20A expression was found in
about 25% of the vaccinated patients, limiting the number of patients
that could display a clinical response. Importantly, no recurrences were
found in the group with a KIF20A+ tumor and all displayed a CTL
response to KIF20A [68]. Two trials were performed in HLA-A*2401+
patients with advanced colorectal cancer failing standard therapy
showing a number of patients with level 3 evidence of vaccine eﬃcacy.
First 18 patients were vaccinated with 5 diﬀerent HLA-A*2401-re-
stricted peptides from several onco-antigens and 2 peptides from
VEGFR1 and VEGFR2. Level 3 evidence was manifested in 7 patients
with 1 CR and 6 SD of 4–7 months. In addition, strong injection site
reactions and an IFNγ-associated T cell response to three or more
peptides, measured after IVS, was associated with longer survival [69].
The second study in 30 patients resulted in 3 PRs and in another 3
patients showing tumor shrinkage not fulﬁlling response evaluation
criteria in solid tumors (RECIST). Nine patients showed an IFNγ-asso-
ciated T cell response to all 7 peptides, measured after IVS. All nine
patients were long term survivors and included 2 PR and 5 SD patients.
The OS of patients responding to all 7 peptides was signiﬁcantly longer
than those responding to 6 peptides or less [70]. A phase II trial in 37
HLA*2402-positive patients with advanced head and neck cancer
evaluated the injection of 3 peptides derived from 3 cancer testis an-
tigens and observed level 3 evidence of vaccine eﬃcacy in 15 patients,
one exhibited a CR and 14 had SD. T-cell reactivity was found in
43–86% of the patients to each peptide. Patients who responded to all
three peptides displayed superior PFS and OS then patients with re-
sponses to 0–1 peptides [71]. Level 3 evidence of cancer vaccine eﬃ-
cacy was also found in 3 out of 6 patients with advanced gastric cancer,
who were vaccinated with an HLA-*2402 restricted peptide from lym-
phocyte antigen 6 complex locus K (LY6K). LY6K is an antigen asso-
ciated with the malignant potential of cancer cells and is overexpressed
in 85% of gastric cancers, albeit not by every cancer cell. A speciﬁc and
robust T cell response was found in 4 patients after IVS but all patients
responded. In one patient, classiﬁed as an SD, vaccination resulted in
the initial shrinkage of 4 out of 5 evaluated tumors and this coincided
with a decrease in serum CEA levels. Two other patients also showed SD
[72]. These data clearly indicate that vaccination with LY6K peptide
can mediate an antitumor eﬀect but also show that immune escape is
imminent when not all tumor cells express the targeted antigen. A
vaccine comprising one HLA*0201 and one HLA-A*2402 restricted
peptide derived from the carcinoembryonic antigen glypican-3 was
injected in 32 patients with refractory ovarian clear cell carcinoma. The
vaccine induced an ex-vivo T cell response in 15 of the 24 tested pa-
tients, measured by IFNγ Elispot. Expression of glypican-3 was found in
8 of 19 tested patients. The tumors of six patients showed reduced HLA
class I expression. The expression of the protein, HLA class I and in-
ﬁltration with TILs was not a predictive marker for survival. Two pa-
tients developed a PR [73], providing level 3 evidence that glypican-3
targeted vaccination may have impact on tumor growth. The ﬁrst pa-
tient displayed multiple metastases before vaccination that rapidly
progressed. A PR was achieved after 10 weeks with some lesions no
longer visible but slow growth of a metastasis in a lymph node. This
metastasis lacked glypican-3 expression and had a reduction in HLA
class I as well as low number of tumor inﬁltrating lymphocytes (TIL).
Concurrent with the PR, pretreatment tumor marker levels in serum
dropped and remained ﬂat until week 60. The second case, showed a
drop in the serum tumor markers after the 7th vaccination and obtained
a PR at week 37. Surprisingly, the primary tumor was glypican-3 ne-
gative but it is known that glypican-3 tumor expression is hetero-
geneous and depends on the location and timing of the biopsies [74].
This is not uncommon and has also been observed for other putative
vaccine targets like XAGE-1b [75].
Overall, among all the patients vaccinated with HLA-A24-restricted
CD8+ T cell epitopes there were ﬁve trials reporting level 1 evidence of
clinical activity while level 3 evidence was found in 6 trials.
PR1 is an HLA-A*0201 restricted peptide that is recognized on
myeloid leukemia cells by preferentially leukemia killing CD8+ T cells.
In a phase 1/2 trial 66 HLA-A*0201 patients with either acute or
chronic myeloid leukemia (AML, CML) or with myelodysplastic syn-
drome (MDS) were vaccinated at diﬀerent dose levels of vaccine. Level
3 evidence of vaccine eﬃcacy was found in 12 patients. PR1-speciﬁc
CD8+ T cells were present in 85% of the patients at baseline. A vac-
cine-induce response, deﬁned as a 2-fold increase in PR1-tetramer+
CD8+ T cells in the blood was observed in 53% of the patients. The
vaccine-induced PR1-speciﬁc CD8+ T cells accumulated within the
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central memory population. The TCR avidity of PR1-speciﬁc CD8+ T
cells after vaccination was higher among the immune responders and
interestingly, it was higher in immune responders with a clinical re-
sponse than in immune responders lacking a clinical response. A more
than 2-fold increase in PR1-speciﬁc T cells after vaccination was not
related to dose or to the percentage of pre-existing PR1-speciﬁc T cells
but was related to a lower disease burden at baseline, ﬁtting with the
other observations that clinical responses primarily were obtained in
patients with low disease burden. Twelve patients showed a clinical
response, 9 of which were immune responders. The other 3 did not
display a vaccine increase in PR1-speciﬁc T cells but the avidity of the
TCR of the pre-existing PR1-speciﬁc T cells changed and was higher
than seen in immune responders without a clinical response or the other
non-responders[76], suggesting that functional avidity maturation of
tumor-speciﬁc T cells, known to be important for responses to viruses
and cancer [77], forms a mechanism through which cancer vaccines
can work.
Wilms’ tumor gene 1 (WT1) is a potent transcriptional regulator, its
expression correlates with cell proliferation and metastatic behavior of
tumor cells. It is overexpressed in many diﬀerent types of tumors [78].
Twenty-ﬁve patients with MDS were vaccinated with a WT1-peptide
vaccine, comprising a CD4+ T cell epitope and a HLA-A*2402-re-
stricted modiﬁed CD8+ T cell epitope. Eleven patients showed a CTL
response as measured by HLA class I-multimers. No overt diﬀerences in
the CTL response were found between patients with clinical beneﬁt and
those having progressive disease. Only ﬁve patients showed a WT-1
speciﬁc DTH response but the relation with clinical response was not
reported, neither was the WT1-speciﬁc CD4+ T cell response reported
[79]. This vaccine was also tested in 32 patients with advanced pan-
creatic cancer in combination with gemcitabine chemotherapy. In 18 of
the patients a WT1-speciﬁc DTH response was observed. Eleven of the
16 patients with longer survival and none of the 7 patients with short
survival showed a DTH response. Patients with a positive WT1-speciﬁc
DTH response displayed superior OS. No diﬀerences were seen with
respect to the number of WT1-speciﬁc CD8+ T cells. However, DTH+
patients displayed more naïve WT1-speciﬁc T cells at baseline and a
signiﬁcantly higher percentage of memory T cells than eﬀector T cells
after treatment than the poor responders [80], suggesting that the poor
responders may have exhausted their WT1-speciﬁc T cell response
while this population is still ﬁt in DTH+ responders. An anchor-mod-
iﬁed HLA-A*2402 restricted 9-mer WT1 peptide was injected in 21
patients with recurrent glioblastoma multiforme (GBM). Vaccination
resulted in 2 PR and 10 SD. All patient tumors expressed WT1, but the
patients with a PR had strong staining of tumor tissue, suggesting that
the level of overexpression matters for clinical eﬃcacy. The clinical
responses could not be associated to the vaccine-induced T cell response
since high frequencies of WT1-speciﬁc T cells were present before
vaccination and did not increase after vaccination, even not in the
clinical responder patients. Unfortunately, no data was presented on the
activation of T cells [81] as a similar maturation of the T cell response
seen after PR1 vaccination [76] may have occurred in these WT1 vac-
cinated clinical responders. Thirty patients in post-remission of AML
but at very high risk of relapse were vaccinated with WT1 messenger
RNA electroporated DCs [82]. Nine patients showed molecular remis-
sion, deﬁned as the normalization of the WT1 mRNA tumor marker in
the blood, 5 of which were sustained for a very long time. Four other
patients showed disease stabilization for a minimum of 2 months. The
survival of the vaccine-responders was signiﬁcantly better than that of
non-responders. Measurement of the circulating WT-1 speciﬁc T cell
response was restricted to the measurement of an HLA-A*0201 re-
stricted epitope but revealed an association between the increase in
WT1-speciﬁc CD8+ T cells and clinical outcome. Notably, the presence
WT1-speciﬁc CD8+ T cells in DTH-inﬁltrating T cells was correlated
with long term clinical responses (at least 3 years). The latter ob-
servation conﬁrms earlier studies in vaccinated melanoma patients,
showing that the presence of TAA-speciﬁc T cells among skin-test
inﬁltrating T cells predict clinical outcome [83]. Thus, WT1-speciﬁc
vaccination shows levels 1a and 1b evidence in multiple trials. Only in
one occasion objective clinical responses were correlated with immune
data, providing level 3 evidence for WT1-targeted vaccine eﬃcacy.
2.2.3. Personalized peptide vaccines based on pre-existing immunity
A series of trials have been performed with so-called personalized
peptide vaccination (PPV). Here, vaccine-peptides are selected from a
warehouse of HLA-class I restricted TAA based on the HLA type of the
patient and the detection of pre-existing peptide-speciﬁc IgG reactivity
against the TAA. Also in these trials levels 1 and 4 of evidence for
vaccine eﬃcacy is provided. In a phase 2 trial, 60 patients with ad-
vanced colorectal cancer failing at least one regimen of chemotherapy
or targeted therapy were vaccinated with a maximum of four peptides
[84]. In 63% of the 51 patients completing at least one series of 6
vaccinations, a CD8+ T cell response was detected by ex-vivo IFNγ
Elispot. IgG responses to the selected peptides were increased in 94% of
the patients. Patients with a concomitant increase in their CTL and IgG
response (possibly reﬂective of CD4+ T cell reactivity) showed a better
prognosis than the others. Both an increased T cell response and the
number of peptides the patient responded to were predictive for fa-
vorable OS, once again suggesting that the magnitude and breadth of
the response to cancer are important determinants. Similar observa-
tions were made in a single arm phase 2 trial where PPV-vaccinated
patients with metastatic upper tract urothelial cancer. An increase in
PPV-speciﬁc IgG reactivity was found in 19 of 37 patients and an IFNγ T
cell response in 17 of 37 patients. Using a landmark time analysis,
patients displaying both a humoral and cellular response to PVV had
better OS than those patients with no, only IgG or only a T cell response
[85]. In another phase 2 randomized trial, castration-resistant prostate
cancer patients received dexamethasone alone or in combination with
PPV. The vaccinated group of 37 patients displayed longer PFS, based
on the level of serum prostate speciﬁc antigens, than the control group
of 35 patients. Median OS was also longer. How the immune response
related to outcome was not reported [86]. In a phase 2 randomized
trial, vaccination of 39 patients with progressive bladder cancer after
ﬁrst-line platinum-based chemotherapy with a maximum of 4 peptides
did not lead to improved PFS when compared to the control group,
albeit that OS was improved. In addition, patients who developed a
response to the vaccine displayed a longer PFS [87]. PPV was also
tested in patients with previously treated advanced NSCLC. Patients
received either docetaxel with PPV or docetaxel with placebo. No dif-
ference in PFS was observed when both groups were compared. Inter-
estingly, within the vaccinated arm those patients displaying vaccine-
induced increases in the peptide-speciﬁc IgG titer of at least 2-fold had a
longer PFS and OS [88]. Another phase 2 randomized trial tested the
addition of low-dose cyclophosphamide, with the intention to attack
regulatory T cells, to PPV in patients with advanced biliary tract cancer
[89]. No diﬀerences in the percentages of Tregs were observed between
cyclophosphamide treated patients and the control group. Vaccine-in-
duced T cell responses were observed in both groups and potentially
were a bit higher in the combination treated patient group. While this
combination group also showed a longer PFS, no clear relationship was
found between the strength of the vaccine-induced immune response
and survival. In summary, vaccine eﬃcacy at the ﬁrst level was found
in 4 trials whereas level 4 evidence was provided in two trials of the 6
trials analyzed.
2.2.4. Vaccines targeting the overexpressed proteins HER2, MUC1 and CEA
The human epidermal growth factor receptor-2 (HER2) is a mole-
cular driver in about a quarter of breast cancers. Antibody therapy to
HER2 has dramatically improved the clinical outcome in breast cancer.
When given in a neoadjuvant setting, 40–60% achieve a pathologic
complete response (pCR) and this is associated with decreased recur-
rence rate and better OS [90,91]. CD4+ Th1 responses to HER2 are
also detected in patients with HER2+ breast cancer but their numbers
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decline with progressive disease. Low numbers of HER2 speciﬁc Th1
cells have been associated with an increased risk to recurrences after
neoadjuvant therapy [92]. Similarly, a preexisting strong HER2-speciﬁc
T cell response (measured by DTH or by IFNγ Elispot) is correlated with
longer PFS in prostate cancer [93]. In breast cancer, elevated levels and
broader reactivity of HER2-speciﬁc Th1 cells as measured by ex-vivo
IFNγ Elispot correlated strongly with pathological CR following
neoadjuvant treatment with HER2 antibody therapy, irrespective of
general immune status of the patients [92]. Hence, vaccination against
HER2 seemed a rational choice. Four patients with a non-pathological
CR to neo-adjuvant therapy showed low numbers of HER2-speciﬁc Th1
cells before vaccination but a strong increase in overall levels and
breadth of the HER2-speciﬁc T-cell response after the injection of au-
tologous DC pulsed with 6 promiscuously HLA class II binding HER2
peptides [92]. The impact of the vaccine was tested in a larger trial,
conﬁrming its capacity to increase the levels and breadth of the HER2-
speciﬁc Th1 response in most patients. However, the detection of these
responses was much lower in the sentinel lymph nodes unless not only
HER2 vaccination but also anti-estrogen therapy was given. Potential
level 3 evidence could be seen as vaccination increased the pathological
CR when the vaccine was given together with anti-estrogen therapy
[94], but the eﬀect anti-estrogen therapy on pathological CR was not
tested. In a large trial with 298 clinically disease-free node-positive and
high-risk node negative breast cancer patients, 153 patients received
AE37 (HER2) + GM-CSF and 145 patients GM-CSF only. The vacci-
nated group showed ex-vivo detectable increased HER2-speciﬁc pro-
liferation and increased numbers of IFNγ-producing HER2-speciﬁc T
cells, for the subgroup of patients tested. No diﬀerences in the recurrent
rate were seen comparing both groups. A preplanned subgroup analysis
revealed that 78% of the vaccinated triple negative breast cancer pa-
tients (with low to intermediate HER2 expression) were still disease free
versus 49% of these patients in the control group [95], providing level 4
evidence for vaccine eﬃcacy.
Mucin-1 (MUC1) is expressed by many solid tumors. TG4010 is a
vaccinia virus-based vaccine expressing full length MUC1 that was used
to vaccinate 148 patients with MUC1-positive NSCLC [96]. Half of the
patient group received cisplatin and gemcitabine chemotherapy
whereas the other half received chemotherapy+TG4010. A longer PFS
was seen in the vaccinated group. A pre-speciﬁed analysis of the CD8+
T cell response using HLA class I-multimer analysis did not reveal a
strong response rate and was not diﬀerent between the two arms [96].
No analysis of the CD4+ T cell response were performed because in a
previous trial the response by CD4+ T cells, measured as a proliferative
index of> 2, was deemed not informative while a response by CD8+ T
cells, measured after a round of in vitro stimulation and found in 12 of
the 21 patients with disease control, was associated with longer time to
progression and OS [97]. Notably, the TG4010 induced MUC1-speciﬁc
CD4+ T cell and CD8+ T cell response was found to be transient in two
diﬀerent trials [97,98]. In addition, a biomarker program had identiﬁed
that the frequency of circulating CD16+CD56+CD69+ lymphocytes
was higher in 37 vaccinated patients with a shorter time to progression
and worse OS [96]. A phase2b/3 trial with 222 patients has been
launched and the predictive value of this cellular biomarker was posi-
tively validated in the 2b part of trial [99]). Potentially, these activated
lymphocytes have a negative eﬀect on the immune system for instance
by killing of DCs, activated CD4+ T cells and activated macrophages
[100]. However, high frequencies were also associated with a higher
incidence of adverse events in the vaccine group [96], suggesting that
this may also underlie the diﬀerence in time to progression. Still, an
increased progression free survival was found in the TG4010 group
when compared to the placebo group, suggesting clinical beneﬁt from
MUC1 vaccination. Overall, these data suggest that the level 1 evidence
obtained in the ﬁrst trial could not be validated in the second trial.
Despite the fact that potential level 4 evidence for vaccine eﬃcacy was
provided there was no strong link to vaccine-induced T cell reactivity.
Carcinoembryonic antigen (CEA) has also been considered as target
antigen for therapeutic vaccines. In the past, we have shown that op-
timal response induction requires a balancing act to ﬁne-tune the an-
titumor eﬀect while lowering intestinal autoimmune pathology [101].
Twenty-seven patients with CEA expressing carcinomas were vacci-
nated with a DNA vaccine encoding an HLA-A*0201 restricted CEA
epitope. This resulted in the detection of CEA-speciﬁc CD8+ T cells in
58% of the patients treated whom displayed no measurable disease at
start of the trial, measured in an ex-vivo IFNγ Elispot assay [102]. Only
a minority of patients with measurable disease showed a reaction to
vaccination, indicative for disease burden associated immune suppres-
sion, and suggesting that is might be better to vaccinate in a minimal
residual disease setting. Patients who reported diarrhea during the trial
had a longer OS. Diarrhea was associated with a drop in the serum CEA
levels (level 2). Most likely diarrhea was a reﬂection of an on-target
autoimmune eﬀect as the CEA peptide was shown to be presented on
malignant and benign tissue, reminiscent of what has been shown after
vaccination with melanoma associated antigens and vitiligo [103].
Also, chimeric antigen receptor T-cell therapy targeting CEA has been
associated with respiratory toxicity due to transient CEA expression on
lung epithelia caused by the precondition regimens [104] and has
shown to induce severe colitis [105]. Potentially, reﬂections of on-
target immunity to healthy tissues might also be seen as a level 3 of
evidence, similar to vitiligo in the skin and severe ocular autoimmunity
through destruction of normal melanocytes in patients with melanoma.
This has been associated with a good eﬃcacy of tumor immunotherapy
[106].
The PANVAC vaccine targets both CEA and MUC1 and was used in a
phase 2 trial to vaccinate 25 patients with metastatic breast cancer of
any subtype in combination with docetaxel chemotherapy [107]. The
23 patients in the control arm received chemotherapy only. In the
vaccine arm 56% of patients showed a CEA- and/or MUC1-speciﬁc
immune response, measured after IVS, while this was the case for 40%
in the control arm. There was a trend visible for improved PFS in the
combination arm [107]. The data on MUC1 and CEA demonstrate that
some of the TAA used in therapeutic vaccines may mediate antitumor
eﬀects but should be targeted with caution.
2.3. Therapeutic eﬃcacy of cancer vaccines to treat virally-induced high
grade lesions and cancers
About 20% of the cancers are induced by viruses, one well-known
virus is human papillomavirus of which especially type 16 (HPV16) is
highly oncogenic and causes tumors in the head and neck region as well
as the anogenital region. Another oncogenic virus is the Merkel-cell
polyomavirus. Both virus-induced cancers can respond to adoptive T
cell therapies [108,109]. In addition, Merkel-cell carcinoma responds
extremely well to PD-1 checkpoint blockade, showing an objective re-
sponse rate of 56% in advanced Merkel-cell carcinoma [110]. This is
much less the case for the HPV-induced carcinoma’s [111]. The most
likely reason for this is the presence of virus-speciﬁc CD4+ and CD8+
T cells in most of the patients with Merkel-cell carcinoma [112] and
lack thereof in the majority of patients with a recurrent HPV-induced
tumor [113–115].
To increase T-cell reactivity to HPV16 several types of vaccines have
been developed which aim to harness the immune system against the
viral oncoproteins E6 and E7, as they are critically involved in tumor-
igenesis. VGX-3100 is a DNA vaccine targeting oncoproteins of HPVs
type 16 and 18. Immunization of patients with high-grade cervical le-
sions resulted in the induction of potent CD4+ Th1 responses and
CD8+ CTL responses [116]. In a randomized phase 2b double blind,
placebo-controlled trial, the vaccine induced regression in 50% of the
107 vaccinated patients with high-grade cervical lesions whereas this
was observed in about 31% of the placebo group [117]. Post-hoc ana-
lyses showed that the regression of lesions was associated with an in-
crease in the number of vaccine-induced T cells responding to E6 as
measured by IFNγ Elispot [117] as well as CD137+CD8+ HPV-speciﬁc
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T cells expressing perforin or granzyme in the blood and an increase in
perforin+ T cells in the tissue [118]. The HPV DNA vaccine GX-188E
also induced signiﬁcant HPV-speciﬁc IFNγ-producing CD4+ and CD8+
polyfunctional T cell responses and the regression of high grade cervical
lesions in 7 of 9 vaccinated patients [119]. ISA101 is an HPV16 syn-
thetic long peptide (SLP) vaccine which was proven to be safe, highly
immunogenic and capable of inducing type 1 CD4+ and CD8+ T cell
responses in patients with HPV16-induced pre-malignant cervical le-
sions [62,120] and HPV16-induced end-stage cervical cancer
[121,122]. Furthermore, it was shown to induce objective regressions
of HPV16-induced high grade vulvar lesions in about 50% of the treated
patients, in two independent trials, whereas spontaneous regression is
only observed in 1.3% of the patients [123,124]. Notably, post-hoc
analyses of the ﬁrst trial showed a strong correlation between the
breadth and magnitude of the ex-vivo vaccine-induced type 1 T cell
response and clinical responsiveness [123,125] and this correlation was
conﬁrmed in the pre-deﬁned analyses performed in a second trial
[124]. Therapeutic ISA101 vaccination of patients with advanced or
recurrent HPV16-positive cervical cancer installed HPV16-speciﬁc T
cell reactivity in patients with a less suppressed immune status but the T
cell response was much weaker than observed before in patients with
HPV16-induced high grade vulvar disease. It also did not result in
clinical responses [126]. Most likely, the lower T cell response was due
to the apparent tumor-mediated leukocytosis observed in these patients
as depletion of circulating CD14+ myeloid cells resulted in increased
detection of T cell reactivity against recall antigens and the HPV16
oncoproteins [127]. In addition, chemotherapy-mediated normalization
of the myeloid cell composition resulted in much stronger T cell re-
sponses to therapeutic vaccination when given to patients with ad-
vanced, recurrent or metastatic cervical cancer [127]. Moreover, it led
to more cure in a mouse model for HPV16-induced cancers [127] and
preliminary reported data reveal clinical beneﬁt in those patients with
the strongest immune response to the vaccine [128]. Upon activation of
tumor-speciﬁc T cells they start to express co-inhibitory markers in-
cluding PD-1 [51] suggesting that more beneﬁt may be achieved when
vaccination is combined with checkpoint blocking. In melanoma,
combination of a TAA peptide vaccine was shown to be safe in com-
bination with nivolumab [129]. In a phase 1/2 trial, patients with in-
curable HPV16-driven oropharyngeal cancers were treated with PD-1
checkpoint blockade and in order to boost the levels of HPV16-speciﬁc
T cells, with the ISA101 HPV16 synthetic long peptide (SLP) vaccine.
This doubled the objective response rate [130], when compared to
earlier data [111].
A second example is vaccination against cytomegalo virus (CMV).
Studies have shown that the CMV-derived phosphoprotein 65 (pp65)
can be expressed in glioblastoma cells but not the surrounding healthy
tissue, suggesting that this protein could function as a virus-derived
tumor-speciﬁc target. In a small randomized and blinded clinical trial in
newly diagnosed glioblastoma 12 patients were treated with autologous
pp65 RNA-pulsed DCs with or without preconditioning of the vaccine
site by injection of recall antigens. Preconditioning increased the ac-
cumulation of the injected DCs in the vaccine site-draining lymph nodes
in a recall antigen-speciﬁc CD4+ T cell-dependent fashion. Not only
did these patients display a better PFS and OS when compared to pa-
tients receiving only the DC vaccine but also the clinical response was
associated with an increase in the number of pp65-speciﬁc IFNγ-pro-
ducing T cells, with the two long term survivors showing the highest
increase in pp65-speciﬁc T cells after vaccination [131]. In a more re-
cent study, the immunogenicity of pp65-DC vaccination in patients with
glioblastoma as well as the correlation between the strength of the
pp65-speciﬁc immune response after vaccination with clinical outcome
was conﬁrmed. Patients whom displayed an OS>40 months had a
much more signiﬁcant expansion in pp65-speciﬁc IFNγ producing T
cells than those with an OS<40 months [132].
In conclusion, there is strong evidence that the T cell response to
viral antigens in human tumors plays an important role in controlling
disease. The therapeutic vaccination trials in patients with pre-
malignant disease provide levels 3 and 4 evidence of vaccine eﬃcacy
and preliminary data suggest that in combination with other im-
munotherapies (e.g. checkpoint blockade) clinical response rates to
immunotherapy go up.
2.4. First signs of successful clinical translation of neoantigen vaccines
Good clinical responses to checkpoint blocking have also been as-
sociated with the presence of high numbers of mutations in tumors and
the presence of T cells speciﬁcally recognizing these mutations [133].
Mutations in the DNA leading to a change in one or more amino acids of
proteins (e.g. point mutations, insertions, deletions, frameshifts or
breakpoints) may lead to a new class of peptides, called neoantigens,
that are presented in MHC class I and II. They activate T cells with high
aﬃnity TCR because they have never been presented in normal tissue
and thus bypass thymic tolerance. Spontaneous activation of neoan-
tigen-speciﬁc CD4+ and CD8+ T cells have been documented in sev-
eral types of tumors by several groups since 1994 [134] and hence
neoantigens became a focus in the development of therapeutic vaccines
[135]. The tools to identify MHC class I and class II-restricted neoan-
tigens have undergone major technical advances allowing for their
rapid identiﬁcation [136]. In several mouse models, it was shown that
neoantigens expressed by tumors not only functioned as targets for
tumor-speciﬁc T cells responding to checkpoint therapy but also that
vaccination with therapeutic long peptide vaccines or poly-epitope
messenger RNA based on these mutant peptides induced tumor re-
gression and rejection comparable to that of checkpoint blockade
[137–140]. These results are similar to what was shown before with
respect to the use of viral oncogene vaccines [30,141].
A deletion mutation aﬀecting exons 2–7 of the EGFR gene
(EGFRvIII) is found in a sizeable fraction of glioblastomas. A peptide
containing the speciﬁc novel amino acid sequence created by this de-
letion mutation was conjugated to keyhole limpet hemocyanin, to in-
crease its immunogenicity. The vaccine, called rindopepimut, has been
tested in several phase 2 trials of patients with gross total resection of
tumor and no evidence of progression after radiotherapy with con-
comitant temozolomide chemotherapy. In a ﬁrst trial with 18 patients
[142], 6 of 14 tested patients showed a rise in mutant-speciﬁc anti-
bodies and this was associated with a better OS. Only 3 of the 17 tested
patients showed a DTH response to the mutant peptide, indicating that
not many patients were able to mount a T cell reaction to this mutant
peptide. These 3 patients displayed an extremely good OS whereas no
diﬀerence in OS was found when patients were grouped according to
their DTH response to recall antigens. Importantly, 82% of the patients
showed loss of EGFRvIII expression in recurrent tumors [142]. In the
second trial, vaccination was performed during two diﬀerent schedules
of temozolomide chemotherapy. In one are 7 of 8 patients displayed a
mutant-speciﬁc DTH response while in the other arm none of the pa-
tients responded. However, no diﬀerences in PFS or OS were seen.
Notably, the increase in DTH reactivity was accompanied by a speciﬁc
reduction in CD4+ T cells, an increase in CD4+ Tregs as well as mu-
tant-peptide speciﬁc antibody titers [143], making one wonder if vac-
cination led to EGFRvIII-speciﬁc Th1 responses. Again in 11 of 12 re-
current tumors the expression of EGFRvIII was lost. Similar
observations were made with respect to antibody titers and EGFRvIII
expression in recurrent tumors in a third trial with 65 patients [144].
Because these trials showed an encouraging PFS and OS when com-
pared to historical controls and despite the fact that EGFRvIII expres-
sion was rapidly lost, a randomized, double-blind, phase 3 trial was
started. However, this study was terminated for futility as no diﬀerence
in OS was seen during a pre-planned interim analysis [145]. Again, loss
of the deletion mutant was seen in about 60% of patients in both groups
but the Ab titers did not diﬀer between patients with loss or persistent
expression of the mutant EGFR, indicating that the humoral response is
not a good immune correlate for clinical responsiveness and reinforces
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the notion that the cellular immune response should be more closely
monitored in order to value better the results obtained in these clinical
studies. The reasons for failure of this trial are highly similar to the
phase 3 trials that failed when TAA-targeting vaccines were used.
With the development of pipelines to identify neoantigens, perso-
nalized vaccine strategies have been developed. A ﬁrst trial with
neoantigen vaccination was performed by Carreno et al. [146].
Neoantigens were identiﬁed in tumors of patients with melanoma,
conﬁrmed to bind to HLA-A*0201 and loaded onto DC for vaccination.
Neoantigen-speciﬁc T cells were detected after one round of IVS and
isolated neoantigen-speciﬁc T cells were shown to recognize en-
dogenously processed mutated proteins, showing their functionality.
Another study utilized 13–20 SLP as vaccine to target up to 20
neoantigens per patient, admixed with poly ICLC in 8 patients with
stage II/IVB melanoma after surgical resection with curative intent. Ex-
vivo IFNγ Elispot analyses revealed immune responses to several pools
of peptides, mostly CD4+ T cell mediated. Neoantigen-speciﬁc CD8+
T cells were detected after one round of IVS and> 30% of the cells
were polyfunctional. Of all injected peptides, 60% were recognized by
CD4+ and 15% by CD8+ T cells. In some, but not all, patients the
vaccine-induced CD4+ and CD8+ T cells were able to recognize au-
tologous tumor cells. Furthermore, CD4+ T cell were shown to respond
to DC exposed to irradiated autologous tumor cells, showing natural
presentation by DC of neoantigens. Interestingly, PD-1 blockade in-
creased the breadth of the neoantigen T cell response [147]. Recently, a
personalized RNA vaccine was tested in 13 patients with stage 3 and 4
melanomas after resection of their metastases and no radio-detectable
lesions [148]. For each patient 10 mutations were selected and en-
gineered into two synthetic RNA encoding 5 linear-connected 27mer
peptides with the mutation in the middle. Patients were vaccinated
percutaneously in the inguinal lymph node as this ensured eﬃcient
uptake of the RNA by DC. All patients completed treatment and T cell
reactivity was detected against 60% of the predicted epitopes, with
each patient responding to at least 3 epitopes. The majority of epitopes
was exclusively targeted by CD4+T cells, and 25% by both CD4+ and
CD8+ T cells. All patients had recent history of recurrent disease and a
high risk for relapse, but vaccination was associated with a strong re-
duction in the longitudinal cumulative recurrent metastatic events
(Level 2). In addition, 3 of 5 patients with a metastasis at start of
vaccination, showed objective clinical responses (1 CR, 1 PR, 1 MR).
The eﬀects seen are reminiscent of the outcomes seen in earlier trials
with autologous tumor material. A DC vaccine with autologous tumor
RNA was tested in 31 metastatic melanoma patients with follow-up to
10 years after the last patient was vaccinated. Based on DTH responses
and in vitro T cell proliferation assays, 16 of 31 displayed reactivity to
tumor loaded DC, 12 were negative and 3 inconclusive, indicating the
induction of a tumor-speciﬁc response. Two patients showed dis-
appearance of lesions, one even with CR for a couple of months, both
later treated with checkpoint therapy and still alive. The presence of an
immune response was associated with a signiﬁcantly better OS and it
was an independent predictor after correction for disease stage and
performance. The 8 patients with> 20 months of survival were all
immune responders [149]. Another trial used irradiated autologous
melanoma cells conjugated to dinitrophenyl – in order to ensure tumor
cell death - and mixed with BCG in order to enhance the vaccine’s
immunogenicity. Vaccination of 126 patients with stage 3b/c mela-
noma in the adjuvant setting revealed that patients with a strong DTH
response to unmodiﬁed autologous tumor cells displayed a 5-year OS of
75% and DFS of 47%, whereas the no to weak DTH responders had a 5-
year OS of 44% and DFS of 26% [150]. Interestingly, 35 vaccinated
patients developed unresectable disease were treated with the CTLA4
checkpoint inhibitor ipilimumab. When compared to a similar group
that had not been vaccinated before, vaccinated patients showed sig-
niﬁcantly more CR, PR and SD as well as longer OS. The antigens to
which the immune system responded in these latter two trials are un-
known but with our current knowledge are likely to involve
neoantigens too. In addition, potential vaccine-induced responses to
TAA expressed by the tumor may have fostered stronger reactivity to
neoantigens as was shown by a trial in which a melanoma patient with
low level of MAGE-speciﬁc CTL in blood after MAGE vaccination dis-
played tumor regression. Using TCR-Vβ cDNA libraries only a few of the
vaccine-induced CTL were found in regressing metastases. However,
they also found other TCR belonging to tumor-speciﬁc CTL enriched in
regressing metastases and detectable in blood only after vaccination.
These CTL recognized a neoantigen in the context of HLA-A2. Its pre-
sentation was increased in the presence of IFNγ suggesting that the
attack of tumor cells by MAGE-speciﬁc CTL may have induced antigen-
spreading of CTL recognizing truly tumor-speciﬁc antigens [151]. Thus,
the ﬁrst data in neoantigen vaccination trials indicate level 2 evidence
for vaccine eﬃcacy, however, it is likely that early autologous tumor
cell based vaccine have triggered neoantigen-speciﬁc T cells. This
makes it likely that also level 3 evidence for neoantigen vaccine eﬃcacy
exists.
2.5. Level 3 evidence for vaccines targeting immune suppressive mechanisms
A new development is the development of vaccines targeting mo-
lecules that suppress antitumor immunity. The transcription factor
hypoxia-inducible factor-1α (HIF-1α) regulates the expression of genes
involved in immunosuppression. Inhibition of HIF-1α increased the
eﬃcacy of tumor-speciﬁc T cells by increasing the production of their
eﬀector molecules and slowed down the growth of cancer cells in the
4T1 breast cancer model [152]. HIF-1α was also found to be a natural
target for CD4+ T cells in patients with triple negative breast cancer.
Three highly homologous peptides elicited type 1 immunity in mice and
reduced mammary tumor growth in the C3(1)Tag basal-like/stem cell
high murine model [153]. So far, no studies have been reported in a
patient setting. Indoleamine 2,3 dioxygenase (IDO) is a potent inhibitor
of T cells in patients with cancer and can be expressed by cancer cells
and by suppressive myeloid cells. Interestingly, spontaneous T cell re-
sponses against IDO are detected in patients with cancer [154]. Level 3
evidence of vaccine eﬃcacy was found in a study where 15 patients,
with stable stage 3/4 NSCLC disease after standard chemotherapy, were
vaccinated with an HLA-A*0201 restricted IDO peptide with imiquimod
ointment as adjuvants applied 8 h before vaccination [155]. All patients
developed an IFNγ-associated T cell response to the IDO peptide, as
measured by Elispot after IVS. Potential on-target autoimmune eﬀects
related to IDO expression in the gastrointestinal tract were found. A
number of patients remained in SD whereas one showed a PR of target
lesions. No correlation was found between IDO expression in the tumor
and clinical response to the vaccine, but the tumor of the patient with a
PR had moderate IDO expression. Interestingly, the patient with PR and
one long term clinical responder (SD for 2 years) showed long term
stabilization of the kynurenine to tryptophan ratio, which is a measure
for IDO activity. Two early progressive patients showed a strong ex-
pression of IDO in their tumor and a strong increase in this ratio. The
IDO pathway is also linked to Treg biology via the induction of Tregs by
IDO+ DC. In this trial, Tregs decreased in all patients during vaccine
therapy [155]. More recently, also pre-existing PD-L1-speciﬁc cytotoxic
T lymphocytes able to kill both PD-L1 expressing malignant lymphoma
cells and normal immune cells, were described. In co-cultures the ad-
dition of PD-L1-speciﬁc CTLs increased the response of virus-speciﬁc
CD8+ T cells in vitro [156–158], suggesting that may induce a similar
eﬀect in vivo. No trials have been performed.
2.6. Vaccines are not necessarily required to induce tumor-speciﬁc CD8+ T
cells
Tumor-speciﬁc vaccines usually focus on the induction of tumor-
speciﬁc CD8+ T cells. With the rising potential to rapidly identify
neoantigens, attempts were made to use them in vaccines for boosting
neoantigen-speciﬁc CD8+ T cells. Recently, the mutational landscape
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was determined in 3 mouse tumor models and peptides with high
likelihood to bind to MHC class I were used for vaccination.
Unexpectedly, most of the peptides were recognized by CD4+ T cells.
Furthermore, vaccination with such CD4+ T cell activating neoanti-
gens induced potent tumor control and complete rejection of progres-
sively growing tumors in mice. As expected [159,160], part of the
mechanism included reshaping of the tumor microenvironment and
antigen spreading by inducing CD8+ T cell responses to other epitopes
[137,140]. The predominant recognition of neoantigens by CD4+ T
cells after vaccination is also observed in humans [146,147]. Also in
other mouse models where tumor-speciﬁc antigens are used, tumor
control by CD4+ T cells is found. CD4 type 1 T-cells against a point
mutation in isocitrate dehydrogenase type 1, a deﬁning mutation in
glioma, suppressed tumor outgrowth of subcutaneous mutant- isocitrate
dehydrogenase type 1+ sarcomas [161]. MUC-1 speciﬁc CD4+ T cells
prevented lung metastasis of MUC1+ tumors in mice [162]. HPV-
speciﬁc IFNγ-producing CD4+ T cells controlled spontaneous cervical
tumor outgrowth and progression in genetically engineered K14-HPV16
transgenic mice [163]. Notably, also the earlier mentioned therapeutic
HPV vaccines are strong inducers of type 1 CD4+ T cell reactivity and
in the trials with HPV16 SLP vaccine a clear relation was found between
the strength of the ex-vivo CD4+ T-cell response and the clinical re-
sponse of patients with vulvar lesions [124,125]. More anecdotal evi-
dence is found in trials with tumor-associated antigens. A pancreatic
cancer patient vaccinated with hTERT displayed a PR and long-term
survival that was associated with a broad type 1 CD4+ T cell response
while no hTERT-speciﬁc CD8+ T cells were found [57]. In depth
analysis of long term NSCLC survivor in complete remission after
hTERT vaccination also showed a broad hTERT-speciﬁc CD4+ T cell
response and antigen-spreading to hTERT epitopes unrelated to the
vaccine, including to one HLA-B7-restricted CD8+ T cell epitope. Such
T cell activity was also observed in other clinical responders but not in
non-responders [57,58]. Level 1 evidence of vaccine eﬃcacy with the
promiscuous HLA class II hTERT peptide was also reported [55]. Fi-
nally, a mixture of 12 MHC class I restricted epitopes and/or a mixture
of 6 helper peptides derived from the melanoma antigens gp100, tyr-
osinase, MART-1, MAGE-A3 and MAGE A1, varying between 14–23
amino acids in length, have been used to vaccinate 175 patients with
measurable stage IV melanoma. CTL responses, measured after IVS by
IFNγ Elispot were found in 28–47% of the treatment groups whereas
helper T cell responses, measured directly in a 5-day proliferation assay,
were found in 40% of treated patients. T-helper reactivity was asso-
ciated with production of IL-2, IL-12p70, IL-5, CXCL9 and CXCL10. Of
the 148 eligible patients, 7 showed a PR and 27% had SD. The PR rate
was higher in the groups receiving helper T cell epitopes. There was no
association between the presence of a CTL response and a clinical re-
sponse or OS. In the group of patients receiving the helper peptides, the
proliferative response to the melanoma peptides but not to the recall
antigen tetanus was strongly associated with the 1 year survival rate
and OS, even after correction for clinical variables. Interestingly, the
overall response rate was the highest in patients responding to both the
CTL and the helper T cell vaccine [164]. Although the authors did not
formally exclude that the longer peptides used – a format known to be
of higher immunogenicity [165] – also induced CTL responses, the data
suggest CD4+ T cell responses are relevant for the control of tumors.
This notion is sustained by the earlier observation that the adoptive
transfer of autologous NY-ESO1-speciﬁc CD4+ T cells induced regres-
sion of refractory metastatic melanoma [166] as well as by the ob-
servation that TIL of clinically responding stage IV melanoma patients
comprise neoantigen-speciﬁc CD4+ T cells [167,168] and the ob-
servation that the infusion of neoepitope-speciﬁc CD4+ T cells medi-
ated tumor regression in patient with cholangiocarcinoma [169].
3. The inﬂuence of host immune factors on vaccination and
survival
3.1. The impact of circulating myeloid cells and granulocytes on vaccine
eﬃcacy
The NSCLC patients vaccinated with GV1001 not only were ex-
amined for their response to vaccination but also analyzed with respect
to the presence and potential impact of immune suppressive myeloid
cells. The PBMC of the patients were analyzed for the presence of two
types of MDSC, the CD14+, HLA-DRlow monocytic MDSC (mMDSC)
and the Lin-, CD33+CD11b+, HLA-DR-MDSC. A group of healthy
donors (not matched for age or sex) were taken as controls. Among the
22 patients, 16 displayed a T cell response. The Lin-, CD33+CD11b+,
HLA-DRneg MDSC were higher in those vaccinated patients lacking an
immune response but as a group the percentage of these MDSC was not
higher than in the healthy controls. The mMDSC were higher in the
patient group and had an impact on OS within the group of immune
responders. A low percentage of mMDSC was associated with longer
PFS (60 vs 7.8 months) and an extended OS (73 vs 21 months) [170].
This was not the only trial where an impact of MDSC on therapy and
survival was observed. In melanoma, patients treated at the point of a
low lymphocyte to monocyte ratio display a worse response to che-
motherapy [171]. In addition, melanoma patients with high levels of
mMDSC experienced worse survival and display lower reactivity to
melanoma associated antigens [172] and display less of a response to
checkpoint therapy [173]. The detection of T cell reactivity against
tumor antigens in combination with the levels of mMDSC also strongly
correlated to survival in melanoma [172–175]. MDSC also deﬁned
survival in breast cancer. Patients who mounted an HER2-speciﬁc T cell
response and had a lower frequency of Lin-, CD33+CD11b+, HLA-DR-
MDSC displayed a higher 5-year survival rate. The patients with high
levels of these MDSC lacked a CD8+ T cell response to HER2 [175].
Manipulation of the levels of diﬀerent myeloid cells may have a
positive impact on vaccine outcome and survival. Patients with pro-
gressive cervical cancer display higher levels of circulating CD14+
myeloid cells, the depletion of which results in the detection of stronger
T cell reactivity to recall antigens and tumor antigens while che-
motherapy-induced normalization of their levels is associated with a
stronger response to therapeutic tumor vaccination [127]. A combina-
tion of TAA-mRNA transfected DC vaccination and docetaxel che-
motherapy resulted in a decline in mMDSC. This decline in mMDSC was
associated with a longer disease speciﬁc survival in prostate cancer
patients [176]. Analyses of the PBMC of 74 metastatic melanoma pa-
tients treated with DC vaccination, revealed that a low expression of
phophatidylethanolamine binding protein 1 (PEBP1) after but not prior
to vaccination, was associated with a poor overall survival after vac-
cination. This was conﬁrmed in a second cohort of 95 patients. PEBP1
expression correlated with genes in T cell responses but inversely with
genes of myeloid cells and STAT3 associated inﬂammation as well as
the myeloid to lymphoid cell ratio. Patients who did well displayed a
rise in PEBP1 after vaccination [177]. The data of these last 3 studies
suggest that a change in the balance between immune promoting versus
immune suppressive myeloid cells increases the tumor-speciﬁc T cell
response and improves patient outcome.
So far MDSC were hard to deﬁne phenotypically and functional
assays were poorly speciﬁc but we have started to deﬁne the function of
each phenotypically deﬁned putative MDSC type in humans using in
vitro sorted MDSC. These analyses revealed strong suppressive function
for the mMDSC, variable suppression by the CD33+ MDSC and no
suppression by the putative CD33- MDSC. Attempts to reduce the MDSC
with gemcitabine, based on mouse models showing decreases in splenic
MDSC and better tumor immunity, failed in patients when focusing on
the frequencies of CD11b+HLA-DRlow/neg MDSC [178], mMDSC or
CD33+ MDSC while the levels of the non-suppressive CD33neg mye-
loid cells dropped steeply [31,32]. Using an easy to reproduce gating
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strategy, we showed that the levels of mMDSC were highly predictive
for survival in ovarian cancer but so were the levels of DC. The ratio
between these cells had a prediction speciﬁcity and sensitivity of 87.5%
for better overall survival [32]. In the TC-1 mouse model it was shown
that the presence of activated macrophage like DCs is important for the
outcome of immune-mediated chemotherapy eﬀect [30,179], and
therapeutic tumor vaccination [180]. In melanoma patients treated
with PD-1 blocking antibodies, the levels of CD14+CD16-HLA-DRhi
(classical monocytes) is associated with longer survival and better re-
sponse to checkpoint therapy [181]. These observations are supported
by the observation that in addition to the number of inﬁltrating CD8+
T cells, also the number of activated DC and ratio of M1 to M2 mac-
rophages not only determines overall survival but also predicts the
response to adoptive T cell therapy in melanoma [182].
Neutrophils, which comprise the population of granulocytic MDSCs
may have a systemic immune suppressive eﬀect in cancer patients. In
the RNActive CV9201 study, targeting 5 TAA in NSCLC patients, the
neutrophil to lymphocyte ratio was inversely correlated with progres-
sion free and overall survival. Furthermore, two mutually exclusive
expression signatures in the peripheral blood characterized patients as
either having a T and NK cell signature or having a myeloid cells and
inﬂammation signature. Patients with the latter signature had shorter
PFS and OS [183]. A high neutrophil to lymphocyte ratio was asso-
ciated with a less broad vaccine-induced T cell response after PPV
vaccination of patients with advanced colorectal cancer [69], indicating
that neutrophils may also impact on the eﬃcacy of the vaccine to sti-
mulate tumor-speciﬁc T cell reactivity.
Altogether, these studies make a strong case for using the levels of
diﬀerent types of circulating myeloid cells (immune suppressive and
stimulatory), in addition to the myeloid to lymphoid ratio and the de-
tection of T cell reactivity for clinical decision support. This notion is
sustained by a recent study in which a peripheral immune score was
developed. The score was based on peripheral immune subsets re-
ﬂecting immune function in a positive way, including central memory
CD4+ and CD8+ T cells, and the ratio of these two subtypes over ICOS
+ Tregs. It also evaluated the levels of potentially negatively acting
immune subsets, indicated by CD4+ or CD8+ T cells expressing more
than two of the CTLA-4, PD-1 and TIM3 checkpoints, the percentages of
ICOS+ Treg, CD11c+ DC expressing PD-L1, CD33+HLA-DRlow/neg
MDSC expressing PD-L1 and that of CD3-CD56+NK cells lacking ex-
pression of Tim3 [184]. The immune cells were assigned to bins based
on tertiles to ensure that patients with similar frequency of a given
subset were assigned to the same bin. Then a score was applied being
zero to the highest bin with an expected negative result or to the lowest
bin if that subset should have a positive response. Conversely, 2 points
were given to the other extreme bins. When pretreatment PBMC of 48
breast cancer patients, whom received either docetaxel or docetaxel
with a PANVAC vaccine, were analyzed with a scoring method based on
classic phenotypes, no association with PFS was found. However, if the
peripheral immune score was applied then a correlation with PFS could
be observed for the vaccine treated group but not in the control arm
[184]. This suggests that the peripheral immune score could help to
identify the patients who beneﬁt the most from vaccination. The pre-
dictive value of this approach then was conﬁrmed in a group of prostate
cancer patients treated with either a bone-seeking radionuclide alone or
in combination with PROSTVAC vaccine. Again, only in the vaccine
arm the peripheral immune score was predictive [184], conﬁrming an
earlier report [185].
3.2. The impact of regulatory T cells and NK cells in trials
A few trials reported that not only MDSC but also regulatory T cells
may mediate an impact on vaccine eﬃcacy and/or on survival. Among
the patients responding with a GV1001-speciﬁc T cell response after
vaccination, those with low frequencies of CD4+CD25+CD127low/
neg Foxp3+ Tregs had signiﬁcantly increased PFS and OS. In addition,
the quality of the T cell response was better as indicated by the higher
IFNγ/IL5 and IFNγ/IL13 ratio [170]. Similarly, breast cancer patients
mounting a CD8+ T cell response to Her2 and having relatively low
frequencies of CD4+Foxp3+CD127lowCD25+ Tregs displayed a better
survival [175]. A subset of CD4+ T cells was shown to suppress tumor
immunity by the action of membrane bound TGFβ in mice [186]. One
study reported that vaccination with the MAGE-A3 may lead to the
induction of such Tregs in patients with metastatic melanoma [187].
Interestingly, disappearance of these CD4+TGFβ+Tregs was observed
in melanoma patients immunologically responding to vaccination – as
measured by DTH test - while in the immunologically non-responding
group the frequencies of CD4+TGFβ+Tregs rose to four times the le-
vels observed in the responders. The stage IV melanoma patients who
showed an immune response to the vaccine had longer progression free
and overall survival [188], suggesting that the vaccine expanded Tregs
have a negative impact on vaccine eﬃcacy and survival. Indeed, T cells
that are genetically engineered to resist TGFβ-signaling were much
more active against mouse melanoma [189]. Vaccine-induced Tregs
were also observed in patients with high grade lesions of the vulva after
HPV16 SLP vaccination. These patients showed a weaker eﬀector T cell
response to the vaccine and were less likely to show objective clinical
responses [125]. However, the observations were not conﬁrmed in a
second study [124].
To interfere with Tregs, inoperable but stable metastatic colorectal
cancer received cyclophosphamide (50mg, twice a day on days 1–7 and
15–21) and were vaccinated with modiﬁed virus Ankara expressing the
tumor antigen 5T4. In 12 of the 27 vaccinated patients the percentage
of CD4+Foxp3+ Tregs dropped with about 40% or more. This de-
crease was associated with better PFS [190]. In another study, meta-
static castration-resistant prostate cancer patients received cyclopho-
sphamide at a 50mg dose, every day for 7 weeks in combination with
PPV vaccination or PPV alone. The decrease in percentage Tregs from
baseline frequencies was higher in the cyclophosphamide arm but so
was an increase in CD33+CD14-MDSC [191], suggesting that unin-
tentionally one suppressive mechanism was replaced by another when
cyclophosphamide is given.
Finally, the frequency of circulating CD16+CD56+CD69+ lym-
phocytes (NK cells) was higher in 37 vaccinated NSCLC patients with a
shorter time to progression and worse OS in a phase 2b trial [96]. The
predictive value of this biomarker was positively validated in a phase
2b/3 trial with 222 NSCLC patients and was only operational in patients
receiving the vaccine as it had no association with survival in non-
vaccinated patients [99]. Potentially, these activated lymphocytes have
a negative eﬀect on the immune system for instance by killing of DCs,
activated CD4 T cells and activated macrophages [100].
4. Conclusions
All sorts of cancer vaccines have been tested in the clinic and with
the exception of a few, most trials did not reveal strong correlations
between vaccine-induced immunity and signs of clinical impact. This is
mostly due the fact that the number of true clinical responders in these
trials is rather low to allow for statistical comparisons, limiting the
analyses to showing that the clinical responders at least did mount a
vaccine-induced type 1 T cell response. There are several reasons to
explain the limited eﬃcacy of vaccines, including: a) the choice for less
immunogenic vaccine platforms reﬂected by a low percentage of pa-
tients responding, the need for in vitro stimulation to detect the re-
sponding T cells and the transient nature of the induced response
[25,27,47,55,66,67,69,96] ; b) the choice to target suboptimal anti-
gens, which are heterogeneous expressed resulting in antigen loss var-
iants and tumor escape [72,145,192] or not dominant enough
[193,194]; and c) the lack of a supportive systemic and tumor en-
vironment in cancer patients, all reducing the potential to obtain suf-
ﬁcient numbers of vaccine-induced tumor-reactive T cells that can enter
the tumor bed and exercise their eﬀects on tumor growth. If a cancer
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vaccine is applied in settings of low disease burden [61,65,68,102,148]
or pre-cancer [116–119,123,124] when immune suppression is ex-
pected to be less, or in a setting that systemic immune suppression is
mitigated [127], the vaccine-induced T cell responses are stronger,
broader and of an Th1 and/or CTL type. This coincided with level 4
evidence for vaccine eﬃcacy in ovarian cancer and in pancreatic cancer
[65,68]. Vaccination of patients with premalignant disease revealed a
good correlation between tumor-speciﬁc Th1/CTL responses and clin-
ical outcome. On the grounds that a type 1 immune contexture of
cancer is associated with better response to therapy [2], extrapolation
of the immune correlation found in patients with premalignant disease
towards patients with cancer is plausible.
Most cancer vaccine trials report level 1 evidence of vaccine eﬃcacy
using survival beneﬁt for immune responders as a surrogate marker for
the detection of an eﬀective antitumor response. While extension of life
is the ultimate goal of immunotherapy, one may wonder how strong
this type of evidence is. In one trial patients were vaccinated with HLA-
A24 restricted peptides. There was no diﬀerence in survival between
vaccinated patients bearing the HLA-A24 restriction element and those
not having this HLA type, yet the immune responders within the HLA-
A24-positive group displayed better survival than those failing to
mount a T cell response [67]. In another randomized trial, no diﬀer-
ences were seen between vaccinated patients or controls, but patients
who developed a humoral response displayed a better clinical outcome
[88]. A similar observation was made in the context of DTH responses
and survival [143]. Furthermore, some studies report that patients with
a response to 7 diﬀerent peptides have a longer survival than those with
a response to 6 peptides [70] whereas in other studies a similar dif-
ference in survival is found for patients responding to 3 peptides versus
0–1 peptides [71,84]. A simple explanation for these observations
would be that the presence or more broader response to the vaccine
rather reﬂects a better immune status of the cancer patients than true
control of tumor growth. This notion is sustained by the regular ob-
servation that higher levels of circulating immune suppressive cells are
associated with a lower response to vaccines and with worse survival.
However, one can’t exclude that a DTH response reﬂects more func-
tional cells or that a broader response prevents escape, thus still reﬂects
valuable data. Therefore, studies presenting level 1 evidence for vaccine
eﬃcacy in the context of assays that control for immune status and the
levels of immune suppressive cells increase the merit of their data. Type
2 evidence, which is more directly related to the behavior of tumors, is
not often used, Changes in the serum levels of the tumor markers PSA,
CEA, CA125 or CA19-9 [59,73,102] can be measured but many tumors
lack appropriate serum tumor markers that truly reﬂect disease burden.
Furthermore, the number and timing of metastatic events [148] as used
for melanoma is not likely to be useful for other types of tumors.
Level 3 evidence was deﬁned as signs of on-target autoimmunity or
regression of individual metastases, objective clinical responses after
vaccination. Two trials in which an overexpressed self-protein was
targeted, reported signs of potential on-target autoimmunity [102,155].
More importantly, there were at least 18 trials showing regression of
premalignant lesions or tumors after vaccination with a series of dif-
ferent antigens over a spectrum of diﬀerent tumors. In general, the
patients with such a clinical response showed a robust or more active
type 1 T cell response [56,57,61,66,69,72,76,82,123–125,148–150]
which in the case of premalignant disease showed a strong correlation
with clinical outcome [123–125]. The regressions of tumors in cancer
patients, albeit a few per trial, form an attest to the capacity of cancer
vaccines to induce a functional immune response, which under the right
– probably less immune suppressive – conditions even can control
tumor growth. Most likely that is the case why only a few trials have
presented level 4 evidence for vaccine eﬃcacy. Vaccination of patients
with premalignant lesions resulted in a strong tumor-speciﬁc Th1/CTL
response and a higher regression rate than in the non-vaccinated con-
trol group [117]. Moreover, vaccination in a minimal residual disease
setting of ovarian cancer using an engineered autologous tumor
vaccine, resulted in tumor-speciﬁc type 1 T cell immunity and pre-
vented against the development of recurrences when compared to non-
vaccinated controls [64]. Similarly, a non-signiﬁcant longer PFS was
found in a trial where vaccination of pancreatic cancer patients was
performed after surgery. However, in this trial HLA-A24+ were vac-
cinated and received gemcitabine, while the HLA-A24-negative patients
received only chemotherapy. Thus, this result should be taken with
some caution [68]. Cancer vaccination potentially is associated with
level 4 evidence in two other trials. The PFS as measured by serum PSA
levels was better in castration resistant prostate cancer patients re-
ceiving PPV with dexamethasone chemotherapy than in those receiving
chemotherapy only. But no immune response was measured [85]. In
addition, PPV vaccination of patients with progressive bladder cancer
resulted in a better OS but not a better PFS than the control group [87].
At this point it is fair to conclude that there are quite a number of
trials in which cancer vaccines induce the required type 1 T cell re-
sponse and regression of lesions or metastases. The immunotherapy of
cancer ﬁeld has realized earlier that currently many vaccine platforms
have been optimized to do their job [24], that is the induction of tumor-
reactive CD4+ and CD8+ T cells to levels allowing ex-vivo detection in
the blood. For the use of cancer vaccines in the treatment of patients
with cancer, new studies will require investigators to address the rea-
sons for successful regressions rather than focusing on signatures as-
sociated with OS in the absence of such regressions. Understanding
what is similar among the level 3–4 responders and where they diﬀer
from non-responders will teach the way to apply the vaccine with the
right co-treatments for the right patient. I expect that many overlaps
will be found with parameters deﬁning the success of other im-
munotherapeutic treatment options.
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